CAS 1622849-43-7

GSK3145095

CAS: 1622849-43-7

GSK3145095 is an orally active inhibitor of RIPK1 with IC50 of 5 nM, with potential immunomodulatory activities and antineoplastic.

Fórmula: C₂₀H₁₇F₂N₅O₂

Pureza: 99.50%

Cor e Forma: Solid

Peso molecular: 397.38

Ref: TM-T15437

GSK 3145095

CAS: 1622849-43-7

Fórmula: C₂₀H₁₇F₂N₅O₂

Pureza: 98%

Cor e Forma: Solid

Peso molecular: 397.3781

Ref: IN-DA01V3KM

GSK3145095

CAS: 1622849-43-7

GSK3145095

Pureza: ≥98%

Peso molecular: 397.38g/mol

Ref: 54-BUP04454

GSK3145095

CAS: 1622849-43-7

GSK3145095 is a small molecule inhibitor, which is a synthetic compound developed by GlaxoSmithKline. It functions as a targeted inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1), a crucial mediator in the signaling pathways that control inflammation and cell death. The source of GSK3145095 is a chemical synthesis designed to inhibit the kinase activity associated with RIPK1.

Fórmula: C₂₀H₁₇F₂N₅O₂

Pureza: Min. 95%

Peso molecular: 397.38 g/mol

Ref: 3D-XPC84943